A lawsuit was filed on behalf of investors in Cocrystal Pharma, Inc. (NASDAQ: COCP) shares over alleged securities laws violations.
San Diego, CA -- (SBWIRE) -- 10/01/2018 -- An investor, who purchased shares of Cocrystal Pharma, Inc. (NASDAQ: COCP), filed a lawsuit over alleged Securities Laws violations by Cocrystal Pharma, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Cocrystal Pharma, Inc. (NASDAQ: COCP) have certain options and for certain investors are short and strict deadlines running. Deadline: November 19, 2018. NASDAQ: COCP investors should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
Cocrystal Pharma, Inc, formerly BioZone Pharmaceuticals, Inc,is a clinical stage biotechnology company that engages in discovering and developing various novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses.
On September 7, 2018, the U.S. Securities and Exchange Commission ("SEC") filed a lawsuit against former officers of BioZone Pharmaceuticals, Inc as well as other individuals and corporations, alleging violations of the federal securities laws. The SEC complaint alleges that defendants were participants in "highly profitable 'pump-and-dump' schemes . . . from 2013 through 2018" in the stock of three public companies, including BioZone, that, "while enriching Defendants by millions of dollars, left retail investors holding virtually worthless shares."
The plaintiff claims that between September 23, 2013 through September 7, 2018, the defendants made false and/or misleading statements and/or failed to disclose that the defendants were engaged in a pump-and-dump scheme to artificially inflate Cocrystal's stock price, that this illicit scheme would result in governmental scrutiny, including from the SEC, that defendants failed to abide by SEC disclosure regulations, and that as a result, defendants' statements about Cocrystal's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Those who purchased shares of Cocrystal Pharma, Inc. (NASDAQ: COCP) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels